EA200000122A1 - СПОСОБ ЛЕЧЕНИЯ СИНДРОМА ВОСПАЛЕННОЙ ТОЛСТОЙ КИШКИ, СПОСОБ ВЫБОРА БЛОКАТОРА LT-β-R И СПОСОБ ИНГИБИРОВАНИЯ ПЕРЕДАЧИ СИГНАЛА ЧЕРЕЗ LT-β-R - Google Patents

СПОСОБ ЛЕЧЕНИЯ СИНДРОМА ВОСПАЛЕННОЙ ТОЛСТОЙ КИШКИ, СПОСОБ ВЫБОРА БЛОКАТОРА LT-β-R И СПОСОБ ИНГИБИРОВАНИЯ ПЕРЕДАЧИ СИГНАЛА ЧЕРЕЗ LT-β-R

Info

Publication number
EA200000122A1
EA200000122A1 EA200000122A EA200000122A EA200000122A1 EA 200000122 A1 EA200000122 A1 EA 200000122A1 EA 200000122 A EA200000122 A EA 200000122A EA 200000122 A EA200000122 A EA 200000122A EA 200000122 A1 EA200000122 A1 EA 200000122A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lymphotoxin
blocker
receptors
relates
inhibiting
Prior art date
Application number
EA200000122A
Other languages
English (en)
Other versions
EA002966B1 (ru
Inventor
Джеффри Л. Браунинг
Кристофер Д. Бенджамин
Паула С. Хохман
Original Assignee
Байоджен, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен, Инк. filed Critical Байоджен, Инк.
Publication of EA200000122A1 publication Critical patent/EA200000122A1/ru
Publication of EA002966B1 publication Critical patent/EA002966B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/143—Lymphotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)

Abstract

Данное изобретение относится к композициям и способам, включающим блокаторы рецепторов к лимфотоксину-β, которые блокируют передачу сигналов через рецепторы к лимфотоксину-β. Блокаторы рецепторов к лимфотоксину-β применимы для лечения лимфоцитопосредованных иммунологических заболеваний и, более конкретно, для ингибирования иммунных ответов, опосредованных Th1-клеткам. Данное изобретение относится к способу лечения синдрома воспаленной толстой кишки у млекопитающего путем введения эффективного количества блокатора рецептора лимфотоксина-β (LT-β-R). Данное изобретение также относится к способу ингибирования передачи сигнала через LT-β-R без ингибирования передачи сигнала через TNF-R путем введения эффективного количества блокатора LT-β-R. Далее, изобретение также относится к способу скрининга для выбора растворимых рецепторов, антител и других агентов, которые блокируют передачу сигналов через рецепторы к LT-β.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000122A 1995-07-21 1996-07-19 СПОСОБ ЛЕЧЕНИЯ СИНДРОМА ВОСПАЛЕННОЙ ТОЛСТОЙ КИШКИ, СПОСОБ ВЫБОРА БЛОКАТОРА РЕЦЕПТОРА ЛИМФОТОКСИНА ( LT-b-R) И СПОСОБ ИНГИБИРОВАНИЯ ПЕРЕДАЧИ СИГНАЛА ЧЕРЕЗ LT-b-R EA002966B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/505,606 US5925351A (en) 1995-07-21 1995-07-21 Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
PCT/US1996/012010 WO1997003687A1 (en) 1995-07-21 1996-07-19 SOLUBLE LYMPHOTOXIN-β RECEPTORS AND ANTI-LYMPHOTOXIN RECEPTOR AND LIGAND ANTIBODIES, AS THERAPEUTIC AGENTS FOR THE TREATMENT OF IMMUNOLOGICAL DISEASE

Publications (2)

Publication Number Publication Date
EA200000122A1 true EA200000122A1 (ru) 2000-06-26
EA002966B1 EA002966B1 (ru) 2002-12-26

Family

ID=24011046

Family Applications (3)

Application Number Title Priority Date Filing Date
EA199800144A EA001200B1 (ru) 1995-07-21 1996-07-19 Фармацевтическая композиция, способ лечения, способ ингибирования иммунного ответа
EA200200503A EA005734B1 (ru) 1995-07-21 1996-07-19 Способ лечения ревматоидного артрита
EA200000122A EA002966B1 (ru) 1995-07-21 1996-07-19 СПОСОБ ЛЕЧЕНИЯ СИНДРОМА ВОСПАЛЕННОЙ ТОЛСТОЙ КИШКИ, СПОСОБ ВЫБОРА БЛОКАТОРА РЕЦЕПТОРА ЛИМФОТОКСИНА ( LT-b-R) И СПОСОБ ИНГИБИРОВАНИЯ ПЕРЕДАЧИ СИГНАЛА ЧЕРЕЗ LT-b-R

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EA199800144A EA001200B1 (ru) 1995-07-21 1996-07-19 Фармацевтическая композиция, способ лечения, способ ингибирования иммунного ответа
EA200200503A EA005734B1 (ru) 1995-07-21 1996-07-19 Способ лечения ревматоидного артрита

Country Status (29)

Country Link
US (6) US5925351A (ru)
EP (2) EP1488799A3 (ru)
JP (3) JP4174563B2 (ru)
KR (2) KR100557258B1 (ru)
CN (3) CN1607005A (ru)
AT (1) ATE279205T1 (ru)
AU (1) AU715407B2 (ru)
BG (1) BG63330B1 (ru)
BR (1) BR9609716A (ru)
CA (1) CA2227477A1 (ru)
CZ (1) CZ298277B6 (ru)
DE (1) DE69633624T2 (ru)
DK (1) DK0840616T3 (ru)
EA (3) EA001200B1 (ru)
EE (1) EE04419B1 (ru)
ES (1) ES2225889T3 (ru)
FI (1) FI980122A (ru)
HK (1) HK1010832A1 (ru)
HU (1) HU227508B1 (ru)
MX (1) MX9800624A (ru)
NO (2) NO327163B1 (ru)
NZ (2) NZ503818A (ru)
PL (1) PL186911B1 (ru)
PT (1) PT840616E (ru)
RO (1) RO121799B1 (ru)
SI (1) SI0840616T1 (ru)
SK (1) SK286409B6 (ru)
TR (1) TR199800091T1 (ru)
WO (1) WO1997003687A1 (ru)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7255854B1 (en) * 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
SI0954333T1 (sl) * 1996-10-25 2006-12-31 Biogen Idec Inc Topni limfotoksin-beta receptorji, anti-limfotoksin receptorska protitelesa in anti-limfotoksin ligandna protitelesa kot terapevtska sredstva za zdravljenje imunoloskih bolezni
CN100382844C (zh) * 1996-10-25 2008-04-23 拜奥根Idec马萨诸塞公司 可溶性β-淋巴毒素受体和抗淋巴毒素受体的抗体以及抗淋巴毒素配体的抗体的用途
AU737106B2 (en) * 1997-04-18 2001-08-09 Biogen, Inc. Type II TGF-beta receptor/immunoglobulin constant region fusion proteins
US7118742B2 (en) * 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
TR200101693T2 (tr) * 1998-01-30 2002-06-21 Biogen, Inc. Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
NZ510560A (en) * 1998-10-09 2003-09-26 Biogen Inc Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
PL353057A1 (en) * 1999-06-28 2003-10-06 Basf Aktiengesellschaft Method for preventing tumoral growth
US6346247B1 (en) 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
YU28503A (sh) * 2000-10-13 2006-05-25 Biogen Inc. Humanizovana anti-lt-beta-r antitela
SI1355942T1 (sl) * 2000-12-07 2009-02-28 Lilly Co Eli Glp-1 fuzijski proteini
WO2002083162A1 (en) * 2001-04-13 2002-10-24 University Of Chicago Use of a cd8+ t cell inhibitory agent in the presence of a cd4+ t cell inhibitory agent for inhibition of transplant rejection
US7265208B2 (en) * 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
WO2003011322A1 (en) * 2001-08-02 2003-02-13 Genset S.A. Agonists and antagonists of genoxin for use in the treatment of metabolic disorders
JP4429726B2 (ja) * 2002-02-08 2010-03-10 ワイス 炎症性応答を調節するための組成物および方法
AU2003248782A1 (en) * 2002-07-01 2004-01-19 Biogen Idec Ma Inc. Humanized anti-lymphotoxin beta receptor antibodies
JP2006504775A (ja) * 2002-10-31 2006-02-09 バイオジェン・アイデック・エムエイ・インコーポレイテッド リンホトキシン経路インヒビターによる免疫学的腎障害の処置
KR20050094819A (ko) * 2002-12-20 2005-09-28 바이오겐 아이덱 엠에이 인코포레이티드 화학요법제와 조합된 림프독소 베타 수용체 약제
WO2004058191A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
EP1641826A2 (en) * 2003-06-27 2006-04-05 Biogen Idec MA Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
WO2005067477A2 (en) * 2003-12-08 2005-07-28 Centocor, Inc. Anti-human lymphotoxin alpha antibodies, compositions, methods and uses
CN1980957A (zh) * 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 受体偶联剂及其治疗用途
EP1814599A4 (en) * 2004-08-03 2008-12-17 Biorexis Pharmaceutical Corp COMBINATION THERAPY WITH TRANSFERRIN FUSION PROTEINS WITH GLP-1
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
WO2006135660A2 (en) * 2005-06-10 2006-12-21 University Of Chicago Therapies involving lymphotoxin beta receptor
AU2006299396A1 (en) * 2005-10-04 2007-04-12 The Johns Hopkins University Compositions and methods for treating inflammation
WO2007109733A2 (en) 2006-03-21 2007-09-27 The Johns Hopkins University Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
ATE524493T1 (de) 2006-07-24 2011-09-15 Biorexis Pharmaceutical Corp Exendin-fusionsproteine
EP2084188A2 (en) * 2006-10-12 2009-08-05 Genentech, Inc. Antibodies to lymphotoxin-alpha
KR20090083958A (ko) * 2006-10-20 2009-08-04 바이오겐 아이덱 엠에이 인코포레이티드 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
US8440185B2 (en) 2006-12-26 2013-05-14 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
CN101951940A (zh) * 2007-03-15 2011-01-19 比奥根艾迪克Ma公司 自身免疫病的治疗
MX2009013410A (es) 2007-06-08 2010-03-22 Biogen Idec Inc Biomarcadores para predecir capacidad de respuesta anti-tnf o sin capacidad de respuesta.
EP2382238A1 (en) * 2008-12-31 2011-11-02 Biogen Idec MA Inc. Anti-lymphotoxin antibodies
CN115925878A (zh) 2015-06-05 2023-04-07 艾比欧公司 用于治疗纤维化的内皮抑素片段和变体
US20210253723A1 (en) * 2018-06-15 2021-08-19 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
WO2020229546A1 (en) 2019-05-14 2020-11-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4758549A (en) * 1983-12-13 1988-07-19 Kabushiki Kaisha Mayashibara Seibutsu Kagaku Kenkyujo Lymphokine, monoclonal antibody specific to the lymphokine and their production and uses
US4959457A (en) * 1984-05-31 1990-09-25 Genentech, Inc. Anti-lymphotoxin
IL75318A (en) * 1984-05-31 1994-08-26 Genentech Inc Recombinant human memotoxin and methods for its recombinant production
GB8529014D0 (en) 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
US4849509A (en) * 1987-02-20 1989-07-18 The Wistar Institute Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies
CA2001756A1 (en) 1988-10-31 1991-04-30 Seiichi Uesugi New human lymphotoxin n-end deletion mutant
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
CA2086264C (en) * 1990-06-27 2002-12-24 Jeffrey L. Browning Surface complexed lymphotoxin
US7030080B2 (en) * 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
US5670149A (en) * 1990-06-27 1997-09-23 Biogen, Inc. Lymphotoxin-β, Lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE397665T1 (de) * 1992-12-04 2008-06-15 Biogen Idec Inc Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon
US5747023A (en) 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
CN1146442C (zh) 1995-01-26 2004-04-21 拜奥根有限公司 作为抗肿瘤剂的淋巴毒素-α/β复合体和抗淋巴毒素-β受体抗体
GB9514518D0 (en) 1995-07-15 1995-09-13 Sod Conseils Rech Applic Guanidine salt inhibitors of NO synthase and cyclooxygenase
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6291207B1 (en) 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
CN100382844C (zh) 1996-10-25 2008-04-23 拜奥根Idec马萨诸塞公司 可溶性β-淋巴毒素受体和抗淋巴毒素受体的抗体以及抗淋巴毒素配体的抗体的用途
US7255854B1 (en) * 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
CA2229449A1 (en) 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
NZ510560A (en) * 1998-10-09 2003-09-26 Biogen Inc Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
YU28503A (sh) * 2000-10-13 2006-05-25 Biogen Inc. Humanizovana anti-lt-beta-r antitela
AU2003248782A1 (en) * 2002-07-01 2004-01-19 Biogen Idec Ma Inc. Humanized anti-lymphotoxin beta receptor antibodies
KR20050094819A (ko) * 2002-12-20 2005-09-28 바이오겐 아이덱 엠에이 인코포레이티드 화학요법제와 조합된 림프독소 베타 수용체 약제
WO2004058191A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
CN1980957A (zh) * 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 受体偶联剂及其治疗用途
JP2009539999A (ja) 2006-06-15 2009-11-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド 第２の薬剤との組み合わせにおいてリンホトキシンベータ受容体結合分子を使用する複合療法

Also Published As

Publication number Publication date
EP0840616A1 (en) 1998-05-13
EA005734B1 (ru) 2005-06-30
EP1488799A2 (en) 2004-12-22
CN1146441C (zh) 2004-04-21
EP1488799A3 (en) 2012-07-18
TR199800091T1 (xx) 1998-04-21
KR100493980B1 (ko) 2005-11-11
JP4174563B2 (ja) 2008-11-05
SK6898A3 (en) 2000-10-09
US5925351A (en) 1999-07-20
HUP9802483A2 (hu) 1999-02-01
US20110046073A1 (en) 2011-02-24
DK0840616T3 (da) 2005-01-31
SK286409B6 (sk) 2008-09-05
RO121799B1 (ro) 2008-05-30
PT840616E (pt) 2004-12-31
EE9800013A (et) 1998-06-15
KR100557258B1 (ko) 2006-03-10
BG102265A (en) 1998-09-30
HUP9802483A3 (en) 2004-08-30
EP0840616B1 (en) 2004-10-13
ATE279205T1 (de) 2004-10-15
FI980122A (fi) 1998-03-19
KR19990035805A (ko) 1999-05-25
US7951371B2 (en) 2011-05-31
MX9800624A (es) 1998-04-30
US20110250200A1 (en) 2011-10-13
NO327163B1 (no) 2009-05-04
AU6591296A (en) 1997-02-18
KR20040107513A (ko) 2004-12-20
BG63330B1 (bg) 2001-10-31
CN1195294A (zh) 1998-10-07
EA200200503A1 (ru) 2002-12-26
NO980172D0 (no) 1998-01-14
BR9609716A (pt) 1999-07-06
DE69633624T2 (de) 2006-03-09
NO980172L (no) 1998-03-23
NZ503818A (en) 2001-08-31
JP2012041350A (ja) 2012-03-01
PL186911B1 (pl) 2004-03-31
FI980122A0 (fi) 1998-01-20
US7427403B2 (en) 2008-09-23
HU227508B1 (en) 2011-07-28
US6669941B1 (en) 2003-12-30
CZ17298A3 (cs) 1999-05-12
CN1607005A (zh) 2005-04-20
JP2007254488A (ja) 2007-10-04
AU715407B2 (en) 2000-02-03
EE04419B1 (et) 2005-02-15
EA199800144A1 (ru) 1998-08-27
PL324622A1 (en) 1998-06-08
CZ298277B6 (cs) 2007-08-15
NO20083842L (no) 1998-03-23
DE69633624D1 (de) 2004-11-18
EA001200B1 (ru) 2000-12-25
HK1010832A1 (en) 1999-07-02
EA002966B1 (ru) 2002-12-26
NZ313441A (en) 2000-07-28
US20050037003A1 (en) 2005-02-17
JPH11510488A (ja) 1999-09-14
US6403087B1 (en) 2002-06-11
ES2225889T3 (es) 2005-03-16
CN1895670A (zh) 2007-01-17
SI0840616T1 (en) 2005-04-30
WO1997003687A1 (en) 1997-02-06
US8455445B2 (en) 2013-06-04
CA2227477A1 (en) 1997-02-06

Similar Documents

Publication Publication Date Title
EA200000122A1 (ru) СПОСОБ ЛЕЧЕНИЯ СИНДРОМА ВОСПАЛЕННОЙ ТОЛСТОЙ КИШКИ, СПОСОБ ВЫБОРА БЛОКАТОРА LT-β-R И СПОСОБ ИНГИБИРОВАНИЯ ПЕРЕДАЧИ СИГНАЛА ЧЕРЕЗ LT-β-R
Körner et al. Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system
Van Lier et al. Induction of T cell proliferation with anti‐CD3 switch‐variant monoclonal antibodies: effects of heavy chain isotype in monocyte‐dependent systems
Mulder et al. T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma.
RU2008126932A (ru) Составы и способы лечения заболеваний и нарушений, связанных с передачей сигналов цитокинами
EA199700265A1 (ru) Добавочный протеин рецептора интерлейкина-1 человека
DK0954333T3 (da) Oplöselige lymfotoksin-beta-receptorer, anti-lymfotoksinreceptor-antistoffer og anti-lymfotoksin-ligandantistoffer som terapeutiske midler til behandling af immunologiske sygdomme
Kempers et al. Variable domain glycosylation of ACPA-IgG: A missing link in the maturation of the ACPA response?
Robijn et al. Schistosoma mansoni eggs excrete specific free oligosaccharides that are detectable in the urine of the human host
Panegyrest et al. The inflammatory reaction of paraneoplastic ganglionitis and encephalitis: an immunohistochemical study
FI922551A (fi) Foerfarande foer skoetsel av septisk chock.
Pirner et al. Evidence for direct anti-heparin-sulphate reactivity in sera of SLE patients
DK1171157T3 (da) Anvendelse af glucose-6-phosphat-isomerase og antistoffer derimod til diagnosticering og behandling af arthritis, og test for anti-arthritis-forbindelser
Lipponi et al. Peripheral neuropathy and multiple myeloma in aging: a case report
EA200000455A1 (ru) Способ выявления отклонений в иммунной системе
Yamanaka et al. Immunohistological detection of B lymphocytes in the rat lymphoid organs by using anti-rat B lymphocyte serum
Wähämaa HMGB1 in inflammation: secretion and function
Sharif The role of cross-reactivity between mycobacteria and joint tissues in the aetiology of rheumatoid arthritis with particular reference to terminal N-acetylglucosamine and 65 kilodalton heat shock protein
NO834535L (no) Fremgangsmaate for affinitetsrensing under anvendelse av monoklonale antistoffer.
EP1723967A3 (en) Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU